001443491 000__ 04683cam\a2200553Ii\4500
001443491 001__ 1443491
001443491 003__ OCoLC
001443491 005__ 20230310003547.0
001443491 006__ m\\\\\o\\d\\\\\\\\
001443491 007__ cr\un\nnnunnun
001443491 008__ 220106s2022\\\\sz\a\\\\o\\\\\001\0\eng\d
001443491 019__ $$a1290840993$$a1291147743$$a1291318041$$a1292354652$$a1294367205$$a1296666872
001443491 020__ $$a9783030805463$$q(electronic bk.)
001443491 020__ $$a3030805468$$q(electronic bk.)
001443491 020__ $$z9783030805456
001443491 020__ $$z303080545X
001443491 0247_ $$a10.1007/978-3-030-80546-3$$2doi
001443491 035__ $$aSP(OCoLC)1291172352
001443491 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCO$$dDCT$$dOCLCF$$dDKU$$dOCLCO$$dN$T$$dSFB$$dUKAHL$$dOCLCQ
001443491 049__ $$aISEA
001443491 050_4 $$aRC280.G4$$bN46 2022
001443491 08204 $$a616.99/46$$223
001443491 24500 $$aNeoadjuvant immunotherapy treatment of localized genitourinary cancers :$$bmultidisciplinary management /$$cAndrea Necchi, Philippe E. Spiess, editors.
001443491 264_1 $$aCham :$$bSpringer,$$c[2022]
001443491 264_4 $$c©2022
001443491 300__ $$a1 online resource :$$billustrations (chiefly color)
001443491 336__ $$atext$$btxt$$2rdacontent
001443491 337__ $$acomputer$$bc$$2rdamedia
001443491 338__ $$aonline resource$$bcr$$2rdacarrier
001443491 347__ $$atext file$$bPDF$$2rda
001443491 500__ $$aIncludes index.
001443491 5050_ $$aIntroduction -- State-of-the art and ongoing developments -- Clinical cases debate: neoadjuvant checkpoint inhibition vs standard chemotherapy -- Slideshow of tumor samples before and after checkpoint inhibition -- Ongoing trials and clinical trials endpoints debate: the role of pathological response as a surrogate of survival endpoints -- State-of-the-art and future role of molecular biomarkers for patient selection -- Background of immunotherapy trials in prostate cancer -- Clinical case debate: immunotherapy vs alternative therapies in the neoadjuvant and adjuvant setting of localized, high-risk prostate cancer -- Cytoreductive nephrectomy in the era of targeted therapy and immunotherapy -- Clinical cases debate: Neoadjuvant vs adjuvant immunotherapy in localized RCC -- Benchmark of surgical safety results -- What the scientific data tell us about predictive biomarkers of immunotherapy efficacy across the GU malignancies -- Clinical cases debate: biomarker-driven patient selection vs unselective perioperative strategies.
001443491 506__ $$aAccess limited to authorized users.
001443491 520__ $$aThis book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint inhibitors in GU tumors, including optimal endpoints and the role of pathologic response as a surrogate endpoint of survival. It also illuminates clinical management of patients with organ-confined GU tumors, such as side effect management and perioperative safety, before providing an overview of biomarker use for patient selection across the early-stage GU malignancies. Lastly, the book provides the reader with the most up-to-date data emerging from clinical trials involving immunotherapy in early-stage GU malignancies. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management provides a comprehensive review of the field, serving as a valuable resource for urologists, medical oncologists, pathologists, fellows in urologic oncology, upper-level residents training in urology and medical oncology, as well as pharmacists interested in RCC clinicians.
001443491 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed January 25, 2022).
001443491 650_0 $$aGenitourinary organs$$xCancer$$xAdjuvant treatment.
001443491 650_0 $$aGenitourinary organs$$xCancer$$xImmunotherapy.
001443491 650_6 $$aAppareil urogénital$$xCancer$$xTraitement adjuvant.
001443491 650_6 $$aAppareil urogénital$$xCancer$$xImmunothérapie.
001443491 655_0 $$aElectronic books.
001443491 7001_ $$aNecchi, Andrea,$$eeditor.
001443491 7001_ $$aSpiess, Philippe E.,$$d1972-$$eeditor.
001443491 77608 $$iPrint version:$$z303080545X$$z9783030805456$$w(OCoLC)1255464234
001443491 852__ $$bebk
001443491 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-80546-3$$zOnline Access$$91397441.1
001443491 909CO $$ooai:library.usi.edu:1443491$$pGLOBAL_SET
001443491 980__ $$aBIB
001443491 980__ $$aEBOOK
001443491 982__ $$aEbook
001443491 983__ $$aOnline
001443491 994__ $$a92$$bISE